EA200300560A1 - Улучшенный способ лечения - Google Patents
Улучшенный способ леченияInfo
- Publication number
- EA200300560A1 EA200300560A1 EA200300560A EA200300560A EA200300560A1 EA 200300560 A1 EA200300560 A1 EA 200300560A1 EA 200300560 A EA200300560 A EA 200300560A EA 200300560 A EA200300560 A EA 200300560A EA 200300560 A1 EA200300560 A1 EA 200300560A1
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- visual impairment
- treatment method
- improved treatment
- agents
- suffer
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
- A61K31/5575—Eicosanoids, e.g. leukotrienes or prostaglandins having a cyclopentane, e.g. prostaglandin E2, prostaglandin F2-alpha
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Ophthalmology & Optometry (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Glass Compositions (AREA)
- Polymers With Sulfur, Phosphorus Or Metals In The Main Chain (AREA)
Abstract
Настоящее изобретение направлено на применение комбинации одного или более средств, способных снижать внутриглазное давление, которые обеспечивают улучшенную эффективность при лечении запущенной глаукомы у таких пациентов, которые страдают выявляемыми нарушениями зрения, при одновременном введении указанных средств. Комбинированное применение также будет иметь преимущество при лечении индивидуумов, нуждающихся в снижении высокого ВГД, таких, которые подвержены воздействию факторов риска, делающих их восприимчивыми к нарушениям зрения.Отчет о международном поиске был опубликован 2003.01.30.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US24812300P | 2000-11-13 | 2000-11-13 | |
PCT/SE2001/002499 WO2002038158A1 (en) | 2000-11-13 | 2001-11-12 | Improved treatment |
Publications (1)
Publication Number | Publication Date |
---|---|
EA200300560A1 true EA200300560A1 (ru) | 2003-10-30 |
Family
ID=22937766
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EA200300560A EA200300560A1 (ru) | 2000-11-13 | 2001-11-12 | Улучшенный способ лечения |
Country Status (17)
Country | Link |
---|---|
US (1) | US20030018079A1 (ru) |
EP (1) | EP1333837A1 (ru) |
JP (1) | JP2004513148A (ru) |
KR (1) | KR20030068150A (ru) |
CN (1) | CN1233324C (ru) |
AR (1) | AR035541A1 (ru) |
AU (1) | AU2002215277A1 (ru) |
BR (1) | BR0115208A (ru) |
CA (1) | CA2426049A1 (ru) |
EA (1) | EA200300560A1 (ru) |
HU (1) | HUP0400548A3 (ru) |
MX (1) | MXPA03004183A (ru) |
NO (1) | NO20032122L (ru) |
NZ (1) | NZ525817A (ru) |
PL (1) | PL362855A1 (ru) |
WO (1) | WO2002038158A1 (ru) |
ZA (1) | ZA200303771B (ru) |
Families Citing this family (22)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TWI298257B (en) | 2001-05-31 | 2008-07-01 | Allergan Inc | Hypotensive lipid and timolol compositions and methods of using same |
EP2241636A1 (en) * | 2002-03-13 | 2010-10-20 | Genomic Health, Inc. | Gene expression profiling in biopsied tumor tissues |
DE60326226D1 (de) * | 2002-03-21 | 2009-04-02 | Cayman Chemical Co | Prostaglandin f2 alpha analoga in kombination mit einem antimikrobiellen mittel zur behandlung von glaukom |
ES2382733T3 (es) | 2002-08-29 | 2012-06-13 | Santen Pharmaceutical Co., Ltd. | Remedio para el glaucoma que comprende un inhibidor de la Rho quinasa y prostaglandinas |
US7074827B2 (en) * | 2002-10-24 | 2006-07-11 | Sucampo Ag (Usa) Inc. | Method for treating ocular hypertension and glaucoma |
ES2444841T3 (es) * | 2002-11-18 | 2014-02-27 | Santen Pharmaceutical Co., Ltd. | Remedio para el glaucoma que comprende inhibidor de Rho cinasa y beta-bloqueante |
US20070093507A1 (en) * | 2003-09-05 | 2007-04-26 | Lambrou George N | Compositions comprising benzo (g) quinoline derivatives and prostaglandin derivatives |
AU2004313688B2 (en) | 2004-01-05 | 2010-08-05 | Nicox S.A. | Prostaglandin nitrooxyderivatives |
PL1759702T3 (pl) * | 2004-05-26 | 2009-06-30 | Bayardo Arturo Jimenez | Sposób wytwarzania roztworu latanoprostu do oczu oraz roztwór otrzymany tym sposobem |
GB0501192D0 (en) * | 2005-01-20 | 2005-03-02 | Resolution Chemicals Ltd | Stable prostaglandin-containing compositions |
WO2006137368A1 (ja) | 2005-06-21 | 2006-12-28 | Kowa Co., Ltd. | 緑内障の予防又は治療剤 |
ES2416334T3 (es) | 2005-07-12 | 2013-07-31 | Kowa Company. Ltd. | Agente para la prevención o el tratamiento del glaucoma |
ITRM20080182A1 (it) | 2008-04-07 | 2009-10-08 | Medivis S R L | Preparato oftalmico a base di dorzolamide e latanoprost per il trattamento topico del glaucoma. |
WO2010119305A1 (en) * | 2009-04-14 | 2010-10-21 | Abdi Ibrahim Ilac Sanayi Ve Ticaret Anonim Sirketi | Using of quaternary ammonium compounds in dissolving of latanoprost |
CN102085175B (zh) * | 2009-12-02 | 2013-01-30 | 沈阳兴齐眼药股份有限公司 | 一种眼用凝胶剂及其制备方法 |
FR2961694B1 (fr) * | 2010-06-29 | 2013-01-25 | Thea Lab | Systeme de delivrance polymerique d'une solution non visqueuse a base de prostaglandine sans conservateur |
US9061034B2 (en) | 2010-07-29 | 2015-06-23 | Allergan, Inc. | Preservative free bimatoprost and timolol solutions |
CA2860453C (en) | 2011-01-24 | 2020-04-28 | Inceptum Research & Therapeutics, Inc. | Compositions comprising a prostaglandin for treating neuropsychiatric conditions |
TW201906614A (zh) | 2011-02-04 | 2019-02-16 | 日商興和股份有限公司 | 青光眼或高眼壓症之預防或治療用之點眼藥 |
CN102389433A (zh) * | 2011-11-04 | 2012-03-28 | 兆科药业(香港)有限公司 | 一种药物组合物及其复方制剂 |
KR20200103042A (ko) | 2017-12-21 | 2020-09-01 | 산텐 세이야꾸 가부시키가이샤 | 세페타프로스트와 Rho 키나아제 저해제의 조합 의약 |
CN111491636A (zh) | 2017-12-21 | 2020-08-04 | 参天制药株式会社 | 奥米帕格的组合 |
-
2001
- 2001-11-09 US US10/035,963 patent/US20030018079A1/en not_active Abandoned
- 2001-11-09 AR ARP010105259A patent/AR035541A1/es not_active Application Discontinuation
- 2001-11-12 BR BR0115208-4A patent/BR0115208A/pt not_active IP Right Cessation
- 2001-11-12 NZ NZ525817A patent/NZ525817A/en unknown
- 2001-11-12 AU AU2002215277A patent/AU2002215277A1/en not_active Abandoned
- 2001-11-12 CA CA002426049A patent/CA2426049A1/en not_active Abandoned
- 2001-11-12 EP EP01983882A patent/EP1333837A1/en not_active Withdrawn
- 2001-11-12 EA EA200300560A patent/EA200300560A1/ru unknown
- 2001-11-12 CN CNB018185924A patent/CN1233324C/zh not_active Expired - Fee Related
- 2001-11-12 WO PCT/SE2001/002499 patent/WO2002038158A1/en not_active Application Discontinuation
- 2001-11-12 HU HU0400548A patent/HUP0400548A3/hu unknown
- 2001-11-12 MX MXPA03004183A patent/MXPA03004183A/es unknown
- 2001-11-12 PL PL01362855A patent/PL362855A1/xx unknown
- 2001-11-12 KR KR10-2003-7006437A patent/KR20030068150A/ko not_active Application Discontinuation
- 2001-11-12 JP JP2002540741A patent/JP2004513148A/ja not_active Withdrawn
-
2003
- 2003-05-12 NO NO20032122A patent/NO20032122L/no unknown
- 2003-05-15 ZA ZA200303771A patent/ZA200303771B/en unknown
Also Published As
Publication number | Publication date |
---|---|
JP2004513148A (ja) | 2004-04-30 |
WO2002038158A8 (en) | 2003-01-30 |
CA2426049A1 (en) | 2002-05-16 |
BR0115208A (pt) | 2003-10-07 |
EP1333837A1 (en) | 2003-08-13 |
NO20032122D0 (no) | 2003-05-12 |
HUP0400548A3 (en) | 2007-05-29 |
MXPA03004183A (es) | 2004-12-02 |
PL362855A1 (en) | 2004-11-02 |
CN1233324C (zh) | 2005-12-28 |
HUP0400548A2 (hu) | 2004-06-28 |
KR20030068150A (ko) | 2003-08-19 |
WO2002038158A1 (en) | 2002-05-16 |
US20030018079A1 (en) | 2003-01-23 |
NZ525817A (en) | 2005-03-24 |
CN1473046A (zh) | 2004-02-04 |
AU2002215277A1 (en) | 2002-05-21 |
AR035541A1 (es) | 2004-06-16 |
NO20032122L (no) | 2003-07-01 |
ZA200303771B (en) | 2004-05-17 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EA200300560A1 (ru) | Улучшенный способ лечения | |
PT868186E (pt) | Utilizacao de certos compostos de isoquinolinossulfonilo para tratamento de glaucoma e isquemia ocular | |
ATE254461T1 (de) | Behandlung von augenschmerzen | |
NO20033617L (no) | Fremgangsmate for behandling av diabetes mellitus | |
ATE355374T1 (de) | Therapeutische agentien und methoden ihrer verwendung zur behandlung von amyloidogenen erkrankungen | |
SE9404196D0 (sv) | New antithrombotic formulation | |
DE69521620D1 (de) | Verwendung von 9-deoxyprostaglandinderivaten zur behandlung von glaukom | |
WO2003092584A3 (en) | Agents which regulate, inhibit, or modulate the activity and/or expression of connective tissue growth factor (ctgf) as a unique means to both lower intraocular pressure and treat glaucomatous retinopathies/optic neuropathies | |
WO2004004757A8 (en) | Treatment for eye disorder | |
HK1020867A1 (en) | The topical use of kappa opioid agonists to treat ocular pain k | |
EA201000386A1 (ru) | Нетоксичные для нервной ткани плазминоген-активирующие факторы для лечения инсульта | |
DK1463563T3 (da) | Superoxiddismutas-mimetika til behandling af öjenlidelser og -sygdomme | |
MXPA03005922A (es) | Metodo para tratar glaucoma ib. | |
EP1297849A4 (en) | CURATIVE AGENT FOR OPTICAL AND SIMILAR NERVE DISEASES | |
ATE359774T1 (de) | Taurinderivate verwendbar in der behandlung von netzhauterkrankungen | |
SE9403160D0 (sv) | Method and means for prevention and treatment of secondary cataract | |
MXPA04001255A (es) | Uso de compuesto para el tratamiento de condiciones que resultan de lesion al nervio corneo despues de lasik y otras cirugias oculares o trauma. | |
EP1365771A4 (en) | METHOD OF TREATING CERTAIN EYE DISEASES | |
ATE344054T1 (de) | Behandlung von okularen neovaskularen erkrankungen | |
WO2002015942A8 (en) | Method for the identification of agents that inhibit or promote cataracts and uses thereof | |
BR0212991A (pt) | Métodos de tratamento oftalmológico utilizando inibidores seletivos de inos | |
NO984190L (no) | FremgangsmÕte for behandling av insomnia | |
DE69832796D1 (de) | Verwendung von mizolastine zur herstellung eines arzneimittels zur behandlung von entzündungen | |
UA37151A (ru) | Способ лечения глаукомы и устройство для его осуществления | |
UA29333A (ru) | Глазная мазь |